MTOR and neoplasm: The molecular heterogeneity of TNBC such as the accumulation of tumor mutation burdens and the activation of pathways like NF-κB, PTEN/PI3K/AKT/mTOR, JAK/STAT, and RTKs, contributes to chemoresistance and tumor progression [33].